ArQule to implement Promax 3-dimensional proteomics database from SBI
Under the terms of the agreement, ArQule will gain access to the SBI database, containing multiple families of computationally derived 3-D protein structures.
By on Mar 9, 2001Under the terms of the agreement, ArQule will gain access to the SBI database, containing multiple families of computationally derived 3-D protein structures.
"Structure is the key to unlocking the coming post-genomic revolution in human medicine," said Edward Maggio, Chairman, President and CEO of SBI. "ArQule is a leader in development of innovative proprietary technologies for drug discovery, collaborating with a growing number of leading pharmaceutical companies. ArQule's subscription to SBI's ProMax database represents continued validation of the value and utility of large-scale protein structural information. SBI is very pleased to be working with ArQule to assist in furthering their objectives."
SBI has developed technologies to generate refined 3-dimensional structural models of proteins from primary genetic information and commercializes these technologies through its structural database products and through drug discovery collaborations with leading pharmaceutical companies.